Ann Intern Med

1. BOEDER N, Butler K
   Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the United States.
   Ann Intern Med. 2025;178:1673.
   

   >> Share

   
   
2. LAPRISE JF, Chesson HW, Markowitz LE, Drolet M, et al
   Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the United States.
   Ann Intern Med. 2025;178:1674-1675.
   

   >> Share

   
   
3. QASEEM A, Wilt TJ, Harrod CS, Obley AJ, et al
   Influenza Vaccines for 2025-2026 in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians.
   Ann Intern Med. 2025 Nov 18. doi: 10.7326/ANNALS-25-04056.
   

   >> Share

   
   
4. 
   Web Exclusive. Annals Video Summary - Comparative Effectiveness and Harm of Seasonal Influenza Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.
   Ann Intern Med. 2025 Nov 18:e2504658VS. doi: 10.7326/ANNALS-25-04658.
   

   >> Share

   
   
5. DOBRESCU AI, Sharifan A, Sommer I, Neubauer-Bruckner CIA, et al
   Comparative Effectiveness and Harm of Seasonal Influenza Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.
   Ann Intern Med. 2025 Nov 18. doi: 10.7326/ANNALS-25-04028.
   

   >> Share

   
   

   
   BMJ

6. TAYLOR L
   CDC website altered to suggest possible link between vaccines and autism.
   BMJ. 2025;391:r2470.
   

   >> Share

   
   

   
   J Gen Virol

7. OHRNBERGER S, Meyer Zu Natrup C, Clever S, Schunemann LM, et al
   Strong immunogenicity and protection against SARS-CoV-2 in hamsters induced by heterologous boost vaccination with an MVA-based COVID-19 vaccine candidate.
   J Gen Virol. 2025;106:002180.
   

   >> Share

   
   
8. ENTRIKEN CG, Bruce KL, Coyne BM, Kruyer SH, et al
   Improved efficacy of an influenza DNA vaccine through high-density microarray patch delivery.
   J Gen Virol. 2025;106:002179.
   

   >> Share

   
   

   
   J Infect

9. WULFFRAAT MT, van de Weijer NG, Wijmenga-Monsuur AJ, Badoux P, et al
   Evolving pneumococcal epidemiology and vaccine impact in the Netherlands, 2004-2024: carriage and invasive disease.
   J Infect. 2025 Nov 13:106658. doi: 10.1016/j.jinf.2025.106658.
   

   >> Share

   
   

   
   J Infect Dis

10. ZHAO W, Yan X, Yang Y
    Letter to the Editor regarding to Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Pneumonia Hospitalization Among Medicare Beneficiaries Aged >/=65 in Long-Term Care.
    J Infect Dis. 2025 Nov 15:jiaf581. doi: 10.1093.
    

    >> Share

    
    

    
    J Virol

11. NOTARIO L, Guerrero-Espinosa E, Nistal M, Lauzurica P, et al
    Thyroid hormone deficiency worsens outcomes in vaccinia virus infection.
    J Virol. 2025 Nov 20:e0129425. doi: 10.1128/jvi.01294.
    

    >> Share

    
    
12. SAENG-CHUTO K, Wang Z, Krueger AC, Bargeron K, et al
    A novel antiviral role of ankyrin repeat and LEM domain-containing 2 (ANKLE2) in restricting vaccinia virus through barrier to autointegration factor (BAF).
    J Virol. 2025 Nov 18:e0154925. doi: 10.1128/jvi.01549.
    

    >> Share

    
    

    
    JAMA

13. PANT S
    2024-2025 COVID-19 Vaccines Protected Against JN.1 Subvariants.
    JAMA. 2025 Nov 14. doi: 10.1001/jama.2025.19733.
    

    >> Share

    
    
14. PANT S
    Updated Flu, RSV Vaccination Recommendations for Immunocompromised People.
    JAMA. 2025 Nov 14. doi: 10.1001/jama.2025.19738.
    

    >> Share

    
    

    
    Lancet

15. YADAV PD, Sahay RR
    Safety and immunogenicity of the Hendra virus recombinant soluble glycoprotein G Nipah virus vaccine in adults.
    Lancet. 2025 Nov 14:S0140-6736(25)02277-9. doi: 10.1016/S0140-6736(25)02277.
    

    >> Share

    
    
16. FRENCK RW JR, Naficy A, Feser J, Dickey MP, et al
    Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study.
    Lancet. 2025 Nov 14:S0140-6736(25)01390-X. doi: 10.1016/S0140-6736(25)01390.
    

    >> Share

    
    

    
    MMWR Morb Mortal Wkly Rep

17. OLMSTED KE, Ramsey-Omonua T, Thomas ES, Lee JT, et al
    Notes from the Field: Expanding Birthing Hospital Enrollment in the Vaccines for Children Program to Increase Infant Immunization Against Respiratory Syncytial Virus - United States, October 2023-March 2025.
    MMWR Morb Mortal Wkly Rep. 2025;74:589-591.
    

    >> Share

    
    

    
    N Engl J Med

18. EL SAHLY HM, Atmar RL
    An Early Look at mRNA Vaccines to Prevent Influenza.
    N Engl J Med. 2025;393:2048-2050.
    

    >> Share

    
    
19. FITZ-PATRICK D, McVinnie DS, Jackson LA, Crowther G, et al
    Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine.
    N Engl J Med. 2025;393:2001-2011.
    

    >> Share

    
    

    
    Pediatr Infect Dis J

20. PEREZ-LATORRE L, Cohen SH, Sanchez PJ, De Antonio R, et al
    SARS-CoV-2 Infection Versus Vaccination During Pregnancy: Implications for Placental Antibody Transfer.
    Pediatr Infect Dis J. 2025 Nov 20. doi: 10.1097/INF.0000000000005032.
    

    >> Share

    
    
21. MARLOW R, Roderick M, Oliver J, Jordan Z, et al
    Quality of Life Impact of Varicella on Children and Their Families in the UK: The QoLPoX Study.
    Pediatr Infect Dis J. 2025;44:1244-1249.
    

    >> Share

    
    

    
    PLoS Comput Biol

22. BILLINGS WZ, Ge Y, Skarlupka AL, Miller SL, et al
    Different antigenic distance metrics generate similar predictions of influenza vaccine response breadth despite moderate correlation.
    PLoS Comput Biol. 2025;21:e1013720.
    

    >> Share

    
    

    
    PLoS One

23. SETHI G, Lakra AK, Nirmal K, Hwang JH, et al
    In silico design of a multi-epitope vaccine against Cryptosporidium parvum using structural and immunoinformatics approaches.
    PLoS One. 2025;20:e0334754.
    

    >> Share

    
    
24. LIMTHONGKUL J, Warit S, Sunintaboon P, Ubol S, et al
    BCG cell wall skeleton augments the immunogenicity of dengue nanoparticle vaccines by promoting dendritic cell activation.
    PLoS One. 2025;20:e0337113.
    

    >> Share

    
    
25. TSEGAW TK, Alemu EA, Arage FG, Tadese ZB, et al
    Geographically weighted regression analysis of incomplete basic childhood vaccination in Sub-Saharan Africa: Evidence from DHS, 2019-2024.
    PLoS One. 2025;20:e0336498.
    

    >> Share

    
    

    
    Vaccine

26. MCGOWAN CR, van Zandvoort K, Ibrahim SA, Hassan AI, et al
    Safety and coverage of Pneumosil pneumococcal polysaccharide conjugate vaccine (10-valent PCV) in a camp for internally displaced persons in Somaliland.
    Vaccine. 2025;69:127991.
    

    >> Share

    
    
27. STRUWIG VA, Ta A, Thorat AV, Ilic A, et al
    Evaluating the implementation of the 20-valent pneumococcal conjugate vaccine for paediatric immunization in Australia.
    Vaccine. 2025;69:127996.
    

    >> Share

    
    
28. LASRADO N, Rossler A, McConnell I, Molloy K, et al
    Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variants.
    Vaccine. 2025;69:127997.
    

    >> Share

    
    
29. ZHONG Y, Yang H, Chai W, Chen D, et al
    Development and immunological evaluation of a Streptococcus suis serotype 2 capsular polysaccharide conjugate vaccine.
    Vaccine. 2025;69:128004.
    

    >> Share

    
    
30. DEVSAM B, Bortolussi K, Tippins J, Vasiliadis S, et al
    The experience of seeking & granting special medical exemptions for mandated vaccines: A scoping review.
    Vaccine. 2025;68:127935.
    

    >> Share

    
    
31. COOPER SC, Williams IV, Porter A, Presti C, et al
    'They're not going to tell you everything': A qualitative study with HPV vaccine hesitant parents and caregivers in the northeast and southeast U.S.
    Vaccine. 2025;68:127948.
    

    >> Share

    
    
32. DAS T, Nath BK, Dhar PK, Peters A, et al
    Safety and immunogenicity of a novel psittacine beak and feather disease vaccine and optimisation of a thermostable spray-dried formulation.
    Vaccine. 2025;69:127989.
    

    >> Share

    
    
33. RUSSO L, Farina S, Macri RA, Pentecost WA, et al
    State-level progress and setbacks in influenza vaccination among adults >/=65: A fifteen-season analysis from 2009/10 to 2023/24.
    Vaccine. 2025;69:127983.
    

    >> Share

    
    
34. NUNO T, Soto S, Sepulveda R, Sierra LA, et al
    The Arizona prevention research center vaccine confidence network: A Mobile health unit intervention and survey results of barriers and facilitators to COVID-19 vaccination.
    Vaccine. 2025;60 Suppl 1:127970.
    

    >> Share

    
    
35. FANG L
    Gene-deletion attenuated live vaccines for Streptococcus suis: Advances, challenges, and future directions.
    Vaccine. 2025;69:127990.
    

    >> Share

    
    
36. RANA MM, Haydel B, Carrara G, Gleason C, et al
    Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIV.
    Vaccine. 2025;69:127969.
    

    >> Share

    
    
37. JOKAR M, Goddard Q, Nobrega D
    Infodemiology of public sentiment toward the measles vaccine in Canada: A google trends and health belief model-based analysis, 2025.
    Vaccine. 2025;69:127998.
    

    >> Share

    
    
38. BIRKETT AJ, Ansah E, Gordon S, Gyapong M, et al
    Value profile for Malaria vaccines and monoclonal antibodies.
    Vaccine. 2025 Nov 15:127971. doi: 10.1016/j.vaccine.2025.127971.
    

    >> Share

    
    
39. MCLAUGHLIN JM, Wassil J
    Response to Anticipated impact of novel adult-specific pneumococcal conjugate vaccine by Joshi et al.
    Vaccine. 2025 Nov 15:127988. doi: 10.1016/j.vaccine.2025.127988.
    

    >> Share

    
    
40. CHAPMAN S, Christodoulaki ME, Davey SA, Gaffiero D, et al
    Understanding vaccine hesitancy: The role of fear and message framing in COVID-19 vaccination intention in adults in the UK.
    Vaccine. 2025;69:127999.
    

    >> Share

    
    
41. MUKHOPADHYAY ES, Bellamy DG, Tinto H, Hamaluba M, et al
    Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [Vaccine 68 (2025) 127897].
    Vaccine. 2025;69:127973.
    

    >> Share

    
    
42. RAUPACH J, Housria Y, Hein S, Schnierle B, et al
    Comparative analysis of a flexible novel vaccine platform based on cell permeable chimeric HBV capsids for mucosal vaccination.
    Vaccine. 2025;69:127987.
    

    >> Share

    
    
43. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Erratum to "Report from the World Health Organization's Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC) meeting, virtual gathering, 1-5 September 2025" [Vaccine 68 (2025) 127903].
    Vaccine. 2025;69:127972.
    

    >> Share

    
    
44. ILBOUDO DP, Simpore A, Sawadogo J, Ouattara AK, et al
    Acceptance, hesitancy, and ethical challenges of the COVID-19 vaccine in sub-Saharan Africa: a systematic review and meta-analysis.
    Vaccine. 2025;69:127966.
    

    >> Share

    
    

    
    Virus Res

45. KHAN A, Mohammad A, Alshabrmi FM, Alatawi EA, et al
    HMPV-TherResDB: Comprehensive Human Metapneumovirus (HMPV) Database for Sequence-Structure Annotations, Vaccine Resources, and Therapeutics Research.
    Virus Res. 2025 Nov 16:199665. doi: 10.1016/j.virusres.2025.199665.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share